Tax Consultant
Pharmaceutical Industry Tax
in Kota Madiun
The pharmaceutical industry in Indonesia operates within a complex multi-layered tax framework that reflects its status as a national strategic sector. Companies face standard 22% corporate income tax, VAT on domestic drug sales, Article 22 import tax on Active Pharmaceutical Ingredients (APIs) and excipients, customs duties on production equipment, and emerging regional taxes on pharmaceutical sales. The industry benefits from significant government incentives including a 300% super deduction for qualifying research and development activities, tax holidays for pioneering investments, and potential import duty exemptions for research equipment. Global supply chains introduce additional complexity through transfer pricing documentation requirements for API imports from related parties, royalty payments for brand licenses, and management fees to parent companies. The interaction between BPOM regulatory compliance, Ministry of Health requirements, and tax obligations demands specialized knowledge of both the pharmaceutical business and Indonesian tax regulations. Arunika Consulting provides comprehensive tax advisory services for pharmaceutical manufacturers navigating Indonesia's pharmaceutical tax landscape.
Local Context for Pharmaceutical Industry Tax in Kota Madiun
Rp 2.420.000
Operational-cost context for Pharmaceutical Industry Tax businesses in Kota Madiun.
KPP Pratama Madiun
Compliance context is tied to the local tax administration area.
Industry Alat Transportation (Kereta Api), Industry Food (Brem & Sambal Pecel), Trade Ritel
Connects Pharmaceutical Industry Tax with related local sectors.
Tax Risk Profile: High Risk
Pharmaceutical imports are strictly regulated. Ensure correct HS code and import duty classification.
See Other Perspectives
This topic is also discussed from akuntansi & teknologi perspective.
Tax Challenges for Pharmaceutical Industry Tax
Multi-Regulation Raw Material Imports
Imports of APIs, excipients, and production equipment trigger Article 22 income tax at varying rates, VAT at 11%, customs duties, and potential anti-dumping duties depending on HS code classification.
R&D Super Deduction Qualification
The 300% super deduction for pharmaceutical R&D requires collaboration with accredited research institutions, patentable or commercializable output, and detailed documentation for each research activity.
Multinational Transfer Pricing
Pharmaceutical companies with overseas parent entities must document transfer pricing for API imports, trademark royalties, technical service fees, and management charges with robust benchmarking analysis.
VAT on Government Hospital Tenders
Drug sales to government hospitals through LPSE tender mechanisms have specific VAT treatment with self-assessment and special payment codes that differ from standard commercial sales.
Regional Tax on Pharmaceutical Sales
Regional taxes under the Central and Regional Government Financial Relations Law (UU HKPD) impose new tax obligations on certain pharmaceutical sales at the local government level.
Arunika Solutions
Import Tax Optimization
Analysis and management of Article 22 income tax, VAT, and customs duties on pharmaceutical raw material and equipment imports with correct HS code classification and facility utilization.
- Optimal import tax burden
- Maintained cash flow
- Full compliance
R&D Incentive Claims
Structured documentation of pharmaceutical R&D activities for 300% super deduction claims, including activity logs, research collaboration agreements, and output verification.
- Reduced tax burden
- Documented R&D activities
- Innovation incentivized
Transfer Pricing Documentation
Comprehensive transfer pricing documentation for all cross-border related party transactions including API imports, royalty payments, and technical service fees with benchmarking analysis.
- No DGT penalties
- Reduced audit risk
- Transparent structure
Government Tender VAT Advisory
Setup of VAT recording and reporting systems for government hospital tender transactions with correct self-assessment procedures and payment code application.
- Correct VAT treatment
- Tender compliance
- No audit findings
Related Regulations
Import Withholding
Income tax on pharmaceutical ingredient imports
Pharma Equipment Import
Import duty on pharmaceutical machinery
R&D Super Deduction
300% super deduction for R&D including drug development
Related Industries
Nearby Areas for Pharmaceutical Industry Tax
Frequently Asked Questions
Frequently Asked Questions
How is Article 22 import tax calculated on pharmaceutical raw materials?
Article 22 income tax on pharmaceutical raw material imports is generally 7.5% of the import value (CIF + import duty + VAT) for importers without API, or 2.5% with API. Certain essential medicines on the national priority list may qualify for reduced rates. Correct HS code classification is essential — misclassification can result in incorrect rates and potential tax assessments.
What tax incentives are available for the pharmaceutical industry?
Several incentives are available: (1) Tax holiday for pioneering pharmaceutical investments with 5-20 year income tax reduction; (2) 300% super deduction for R&D activities conducted in Indonesia under PMK-153/2020; (3) Import duty exemption for research equipment and certain production machinery through the Masterlist facility; (4) Tax allowance for new investments in pharmaceutical production facilities providing 30% net income reduction over 6 years.
How is VAT managed on drug sales to government hospitals?
Drug sales to government hospitals through LPSE tender processes use a self-assessment VAT mechanism. The seller issues a standard tax invoice but the VAT is paid by the government hospital through a special payment code rather than being collected from the seller. Proper setup of the VAT recording system for tender transactions is essential to avoid reconciliation issues during audits.
Is transfer pricing a significant issue for multinational pharmaceutical companies?
Yes, multinational pharmaceutical companies with overseas parent entities face stringent transfer pricing requirements. Key related party transactions include API imports (tangible goods pricing), brand and trademark royalties (intangible property), technical assistance and know-how fees, and management charges. Each transaction requires a benchmarking study demonstrating arm's length pricing, and the documentation must be updated annually.
What tax record-keeping is required for pharmaceutical R&D claims?
To claim the 300% R&D super deduction, companies must maintain detailed records including: research activity plans and budgets, collaboration agreements with accredited research institutions, personnel and equipment allocation logs, patent applications or evidence of commercializable output, and financial records separating R&D expenditure from operational costs. The documentation must be sufficient to satisfy a DGT examination.
Ready to Optimize Your Tax Compliance?
Free consultation with our tax experts in Kota Madiun. Specialized for Pharmaceutical Industry Tax businesses.
Contact Us via WhatsAppQuick response within 24 hours